• Publications
  • Influence
Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its
The aim of the presented work was to identify the phase I and II metabolites of MDPV and the human cytochrome-P450 (CYP) isoenzymes responsible for its main metabolic step(s), and the detectability of M DPV in urine by the authors' systematic toxicological analysis (STA). Expand
Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry
The STA procedure allowed the detection of mephedrone, butylone, methylone, and their metabolites in urine of rats treated with doses corresponding to those reported for abuse of amphetamines and should be suitable for proof of an intake of the bk-designer drugs in human urine. Expand
Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy').
The phase I and II metabolites of the designer drugs methylenedioxyamphetamine, MDA, MDMA, MDE, R,S-methylenedioxymethamphetamine (MDMA) and R, S-N-methyl-benzodioxazolylbutanamine (MBDB) were identified and GC-MS procedures were developed for the toxicological analysis in urine and plasma. Expand
Environmental risk assessment of medicinal products for human use according to European Commission recommendations
An environmental risk assessment (ERA) of a selected group of pharmaceuticals for Phase I, environmental exposure assessment, and Phase II Tier A, initial environmental fate and effect analysis of the highest‐selling human drug substances in Germany is presented. Expand
Intrahepatic Cholestasis Following Abuse of Powdered Kratom (Mitragyna speciosa)
A case of a young man who presented with jaundice and pruritus after intake of kratom for 2 weeks in the absence of any other causative agent is described, the first published case of intrahepatic cholestasis after kratom abuse. Expand
Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives
English-language publications from 1995 to 2000 were reviewed and papers describing identification of metabolites or cytochrome P450 isoenzyme-dependent metabolism and papers containing pharmacokinetic/toxicokinetic data were considered and summarized. Expand
The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers
The different pharmacokinetic properties of the MDMA enantiomers may be caused by enantioselective metabolism by CYP2C19 and CYD2D6. Expand
Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine
The detection times of these drugs and/or their metabolites in biological samples are summarized and the implications of the presented data on the possible interactions of drugs of abuse with other xenobiotics, ie, inhibition or induction of individual polymorphic and nonpolymorphic isoenzymes, discussed. Expand
Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to
  • H. Maurer
  • Medicine
  • Clinical biochemistry
  • 1 April 2005
These procedures are relevant tools in clinical and forensic toxicology, and cover analysis of amphetamines, cocaine, hallucinogens, opioids, anesthetics, hypnotics, benzodiazepines, antidepressants, neuroleptics, antihistamines, sulfonylurea-type antidiabetics, beta-blockers, and other cardiac drugs. Expand